Sovleplenib

Small molecule

Also known as HMPL-523

Filedunder review

Evidence outlook · regulatory review

Immune Thrombocytopenia: application under FDA review

US FDA Orphan Drug Designation for sovleplenib in primary ITP (2026-10-29). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

No registered studies for this indication.

Competitive landscape

This drug's own stage for Immune Thrombocytopenia: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sovleplenib: this drugStage not on recordSmall moleculeSykReliable signal
NCT05029635: ESLIM-01 (Lancet Haematology 2024): durable response rate 48.4% (sovleplenib) vs 0% (placebo), p<0.0001; overall response rate 70.6% vs 16.1%.
Fostamatinib (Tavalisse)ApprovedSmall moleculeSpleen tyrosine kinase (Syk)not yet gradedNo reviewed efficacy summary in this indication
RilzabrutinibApprovedSmall moleculeBTKReliable signalNo reviewed efficacy summary in this indication
CID-103Phase 2Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

5 November 2026Priority reviewUS FDA Orphan Drug Designation for sovleplenib in AIHA
US, FDA · HUTCHMED · Source ↗
29 October 2026Priority reviewUS FDA Orphan Drug Designation for sovleplenib in primary ITP
US, FDA · HUTCHMED · Source ↗